High Efficiency Retroviral Mediated Gene Transduction into Single Isolated Immature and Replatable CD34\(^3\) Hematopoietic Stem/Progenitor Cells from Human Umbilical Cord Blood

By Li Lu,*† Mang Xiao,*‡ D. Wade Clapp,§ Zhi-Hua Li,*¶ and Hal E. Broxmeyer*‡¶

From the Departments of *Medicine (Hematology/Oncology), †Microbiology/Immunology, §Pediatrics, the ¶Walther Oncology Center, and the ¶Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, Indiana 46202-5121

Summary

Umbilical cord blood is rich in hematopoietic stem and progenitor cells and has recently been used successfully in the clinic as an alternative source of engrafting and marrow repopulating cells. With the likelihood that cord blood stem/progenitor cells will be used for gene therapy to correct genetic disorders, we evaluated if a TK-neo gene could be directly transduced in a stable manner into single isolated subsets of purified immature hematopoietic cells that demonstrate self-renewed ability as estimated by colony replating capacity. Sorted CD34\(^3\) cells from cord blood were prestimulated with erythropoietin (Epo), steel factor (SLF), interleukin (IL)-3, and granulocyte-macrophage colony stimulating factor (GM-CSF) and transduced with the gene in two ways. CD34\(^3\) cells were incubated with retroviral-containing supernatant from TK-neo vector-producing cells, washed, and plated directly or sorted as CD34\(^3\) cells into single wells containing a single cell or 10 cells. Alternatively, CD34\(^3\) cells were sorted as a single cell/well and then incubated with viral supernatant. These cells were cultured with Epo, SLF, IL-3, and GM-CSF ± G418. The TK-neo gene was introduced at very high efficiency into low numbers of or isolated single purified CD34\(^3\) immature hematopoietic cells without stromal cells as a source of virus or accessory cells. Proviral integration was detected in primary G418-resistant(R) colonies derived from single immature hematopoietic cells, and in cells from replated colonies derived from G418\(^-\)–colony forming unit-granulocyte erythroid macrophage megakaryocyte (CFU-GEMM) and -high proliferative potential colony forming cells (HPP-CFC). This demonstrates stable expression of the transduced gene into single purified stem/progenitor cells with replating capacity, results that should be applicable for future clinical studies that may utilize selected subsets of stem/progenitor cells for gene therapy.

Foreign genes have been introduced into mammalian cells (1, 2), and gene therapy has been evaluated as a possible option in patients for treatment of certain inherited diseases (3, 4). Retroviral-vectors have been used most often to stably transduce genes into cells, and targets for these genes have included hematopoietic stem/progenitor cells (5–20), lymphocytes (21), and tumor cells (22). Hematopoietic stem and progenitor cells are found in low frequency in blood forming tissue, but it is these rare cells that present a viable target for gene therapy. In humans, although antigenic determinants specific for stem and progenitor cells have not yet been identified, these cells contain CD34 antigens and this antigenic determinant has been used successfully as a marker to highly enrich stem and progenitor cells in human adult bone marrow (23–25), blood (20), and umbilical cord blood (25). Cord blood, which contains hematopoietic stem/progenitor cells at a frequency equal to or greater than that of adult bone marrow (26–29) and has a high quality for proliferation (26–29) and self-renewal (25, 30, 31) has shown promise clinically, as an alternative source of human transplantable and marrow repopulating cells (32–36). Recently, it has been demonstrated that cord blood progenitors and long-term culture initiating cells present in a relatively unseparated population of cells are more efficiently transduced by retroviral-mediated gene transfer than are these cells in adult bone marrow (37). For logistic reasons, including the amount of viral supernatant available for gene transduction, purified populations of human stem, and progenitor cells will most likely serve increasingly as targets for future clinical gene therapy procedures. In this context, cord blood is an interesting choice for this source.
of cells especially for autologous transplantation for in utero-diagnosed genetic disorders. For these reasons we chose to evaluate the efficiency of retroviral-mediated gene transduction into highly enriched populations of human cord blood stem and progenitor cells. Future insights will no doubt allow for antigenic characterization of distinct subsets of stem and progenitor cells differing in capacity for self-renewal, proliferation, and lineage-specific differentiation that could potentially be used for selective transplantation. Since the growth of isolated single cell-sorted human stem/progenitor cells is possible (25, 38, 39), we also evaluated the capacity to transduce genes into single isolated CD34+ cord blood cells with extensive reprogramming capacity (a measure of self-renewal). We show that populations of CD34+ cord blood high proliferative potential colony forming cells (HPP-CFC), and multipotential CFU-granulocyte erythroid macrophage megakaryocyte (CFU-GEMM), burst forming unit-erythroid (BFU-E), and CFU-granulocyte-macrophage (GM) progenitor cells can be retrovirally transduced with a TK-neo gene at very high efficiency. This is accomplished also at the single isolated CD34+ cell level, with the gene stably integrated into cells with high reprogramming capacity.

Materials and Methods

Cells and Cell Separation. Cells were obtained from normal human umbilical cord blood scheduled for discard after delivery of the infant and after prior need for samples for clinical study had been satisfied. CD34+ cells were obtained after sorting nonadherent low density T lymphocyte depleted (NALT-) cells on a Dual Laser Flow Cytometer (Epic 753; Coulter Corp., Hialeah, FL) (25). This population was >98% pure for cells expressing the CD34 antigen. CD34+ cells included the 20% of CD34 antigen expressing cells with the highest density distribution of CD34 antigens. This fraction is richest in stem/progenitor cells (23, 25).

In some experiments, CD34+ cells were sorted or resorted using an auto-clone device (Coulter Corp.) into single wells, as a single cell or as 10 cells, containing 0.1 ml semisolid or liquid culture medium (25, 39).

Colony Assay and Replating Experiments. Cultures contained IMDM (GIBCO BRL, Gaithersburg, MD), 1% methylcellulose, 30% FCS (Hyclone Laboratories, Inc., Logan, UT), 0.1 mM hemin (Eastman Kodak Co., Rochester, NY) and recombinant human (rh) erythropoietin (Epo) (Ampgen Corp., Thousand Oaks, CA), rh steel factor (SLF), rh IL-3, and rh-GM-CSF (gifts from Immunex Corp., Seattle, WA). Colonies were scored after incubation at 37°C, lowered (5%) CO2, and 5% CO2 for 14 or 21 d. Replating experiments were performed after removing and dispensing a single colony into the same type of semisolid medium and growth factors as the primary culture (25). Results are given as the mean or mean ± 1 SEM.

Retroviral Vector. The N2/ZipTKNEO (TKNEO) vector used in these studies has been described previously (37). Neo phosphotransferase sequences are expressed in the sense orientation (relative to the 5' long terminal repeat-LTR) via the herpes simplex virus thymidine kinase promoter. GP+EcoAM 12-TKNEO producer cells containing the TKNEO retroviral plasmid were cultured in IMDM containing 10% FCS. Viral-containing supernatant was collected by adding 10 ml of IMDM plus 20% FCS to confluent plates overnight. Harvested medium was filtered through 0.45 μm filters and stored at -80°C until use. The TKNEO virus was titered at 1 x 10^6 G418-resistant CFU/ml on NIH 3T3 cells.

Retroviral Transduction Protocol. Two protocols were used in these studies. In the first protocol, NALT- or CD34+ cord blood cells (<5 x 10^5 cells/ml) were pretreated with Epo (1 U/ml), SLF (50 ng/ml), IL-3 (200 U/ml), and GM-CSF (200 U/ml) at 37°C, 5% CO2, and 20% O2 for 40 h. 1 ml viral supernatant and 8 ml polybrene were added to cells × 4 at 2-h intervals. Cells were washed twice and assayed for colony formation or resorted into single wells containing either a single cell or 10 cells in the presence of 1 U/ml Epo, 50 ng/ml SLF, 200 U/ml IL-3, and 200 U/ml GM-CSF ± 1.5 mg/ml or 12 μg/ml (dry weight) G418. In the second protocol, single CD34+ cord blood cells were sorted into single wells containing 0.1 ml methylcellulose culture in the presence of cytokines as described above (25). 3 or 4 d later, viral supernatant was added only once at 20 μl/well with polybrene (8 μg/ml). G418 was added at 1.5 mg/ml or 12 μg/ml 40 h after addition of viral supernatant.

To assay the temperature sensitivity of the virus preparation, 1000 NIH 3T3 cells were plated in 35-mm tissue culture dishes. Viral supernatant was added for 2.5 h with 8 μg/ml polybrene, cells were washed, and fresh medium added with 1.5 mg/ml (dry weight) G418.

Polymerase Chain Reaction (PCR) Analysis. Genomic DNA was isolated from individual colonies as described by others (40) with modification. Individual colonies were removed from primary or secondary methylcellulose culture or cells were removed after suspension culture and washed with 1 ml of PBS. Cell pellets were resuspended in the small volume of remaining PBS to which was added 200 μl of a chexol 100 solution (41). Cells were lysed by boiling for 5 min, chilled on ice for 5 min, and pelleted for 30 s at 2,800 g. 10 μl of supernatant from the lysate was used for PCR.

As a positive control, DNA was obtained from cells incubated with viral supernatant that contained the TKNEO gene. As a negative control, DNA was obtained from cells incubated with supernatant not containing the TKNEO gene (mock control). Two 27-bp oligonucleotides were used at 20 pmol in the PCR reaction. The PCR generated a 792-bp fragment of the TKNEO gene beginning with the 5'-oligo-[27-bp] 5'CAGATGGATGCACCGAGTCTCAGCGAAACCTGGTC. Each sample was amplified for 30 cycles (94°C for 60 s to denature the DNA, 60°C for 2 min for primer annealing, and 72°C for 3 min for primer extension) as described (17). 20 μl of reaction mixture was electrophoresed on a 1% agarose gel and this was photographed after ethidium bromide staining. Electro-phoresed DNA was then transferred to Gene Screen Plus (Dupont-NEN, Boston, MA) and hybridized with [32P]dCTP-labeled neo fragment. Hybridization was performed overnight at 42°C (17). Filters were washed with 0.1% SDS, 0.1x SSC (SSC = 0.15 M NaCl, 0.015 M sodium citrate) at 55°C, dried, and exposed to Kodak XAR film at -80°C.

Results

Gene Transduction into Early Hematopoietic Cells as Evaluated by G418-Colonies. Before evaluating the transducing efficiency of TK-neo gene into purified populations of cord

---

1 Abbreviations used in this paper: BFU-E, burst forming unit erythroid; Epo, erythropoietin; GEMM, granulocyte erythroid macrophage megakaryocyte; HPP-CFC, high proliferative potential colony forming cells; NALT-, nonadherent low density T lymphocyte depleted; rh, recominant human; SLF, steel factor; TKNEO, N2/ZipTKNEO.
blood progenitor cells, progenitors present in a NALT- population of cells were used as targets. As shown in Table 1, 25% of total progenitor cell-derived colonies were G418<sup>+</sup>. Over 50 G418<sup>+</sup> colonies were separately removed and each one was found by PCR analysis to contain the TK-neo gene. Similar studies were performed using populations of very highly enriched progenitor cells present in CD34<sup>+</sup> populations of sorted cells in which at least 50–75% of the cells are CFU-GEMM, BFU-E, CFU-GM, and HPP-CFC (23, 25). Incubation of CD34<sup>+</sup> cells with the TK-neo gene, followed by washing and plating at 250 cells/ml resulted in a TK-neo gene transduction efficiency similar to that noted for the NALT- population of cells (Table 1). Interestingly, the apparent efficiency of gene transduction was even greater when the CD34<sup>+</sup> cells that were incubated with viral supernatant and then washed were resorted as 10 or 1 CD34<sup>+</sup> cell(s)/well (Table 1). With one CD34<sup>+</sup> cell/well, a 49% transduction efficiency was noted for G418<sup>+</sup> colonies with 45, 25, and 85% transduction apparent, respectively, for CFU-GEMM-, BFU-E-, and CFU-GM-derived colonies. Confirmation of the TK-neo gene in 96% of these G418<sup>+</sup> colonies (129 positive from 135 evaluated colonies) was obtained by PCR analysis of the cells from individual colonies. A breakdown of the different colony types showed that 98% (60/61) CFU-GEMM-, 89% (24/27) BFU-E-, and 97% (30/31) CFU-GM–G418<sup>+</sup> colonies contained the TK-neo gene. High efficiency transduction was also observed in cells growing in suspension from single sorted cells (8 of 8 wells positive by PCR). As seen in Table 1, only a small percentage of G418<sup>+</sup>–HPP-CFC derived colonies were observed; 7 of 7 G418<sup>+</sup>–HPP-CFC colonies were documented by PCR analysis to contain the TK-neo gene.

**Gene Transduction into Early Hematopoietic Cells as Evaluated by Plating Cells in the Absence of G418.** To evaluate the

| Cells analyzed from: | Total No. experiments | Percent G418<sup>+</sup>-colonies |
|---------------------|-----------------------|-----------------------------------|
|                     |                       | Total | HPP-CFC | CFU-GEMM |
| TK-neo and plated at 250 cells/ml | 4 | 83 (38/46)* | 83 (29/35) | 82 (9/11) |
| 10 cells/well       | 3 | 65 (13/20) | 67 (6/9) | 64 (7/11) |
| 1 cell/well         | 3 | 45 (9/20) | 75 (6/8) | 25 (3/12) |
| Suspension cultures produce from 1 cell/well | 1 | 50 (4/8 wells) |
| Primary colonies from cells cultured with mock supernatant and plated as 1 cell/well (background) | 2 | 0 (0/8) | 0 (0/5) | 0 (0/3) |

* Numbers in parentheses represent the number of PCR positive colonies/total number of colonies evaluated.
possibility that the transduction of the TK-neo gene was greater than that observed in Table 1, especially for HPP-CFC derived colonies, CD34+ cord blood cells were incubated with TK-neo genes containing viral supernatant, washed, and plated as 250 cells/ml or resorted as 10 or 1 CD34+ cell(s)/well in the absence of G418. Colonies were then assessed for transduction of the TK-neo gene by PCR analysis. As noted in Table 2, HPP-CFC- and CFU-GEMM–colonies were transduced at high efficiencies, respectively, of 67–83% and 25–82%. Additionally four of eight wells seeded with a single CD34+ cell/well generated cells in suspension culture that contained the TK-neo gene. None of eight colonies derived from mock-infected CD34+ cells were found positive by PCR analysis for the TK-neo gene.

**Gene Transduction at the Single Isolated CD34+ Progenitor Cell Level.** The experiments shown in Table 1 and 2 in which CD34+ cells were first incubated with viral supernatant containing the TK-neo gene and then resorted as a single CD34+ cell/well demonstrated that progenitor cells transduced with the TK-neo gene could proliferate and differentiate in the presence of growth stimulating cytokines but in the absence of other progenitor or accessory cells at the start of the culture. We additionally wished to determine if a single isolated CD34+ cell could be transduced with the TK-neo gene. CD34+ cells were sorted as a single cell/well and viral supernatant containing the TK-neo gene added as described in the Materials and Methods with the subsequent addition to these single cell cultures of either 1.5 mg/ml or 12 μg/ml G418 (Table 3). Based on the findings that HPP-CFC in the absence of G418 could be transduced with the TK-neo gene at high efficiency (Table 2), but few HPP-CFC–G418- colonies formed in the presence of 1.5 mg/ml G418 (Table 1), we had evaluated the sensitivity of HPP-CFC to inhibition by G418. This had not been previously done. HPP-CFC were found to be ultrasensitive to inhibition by G418 such that as little as 12 μg/ml G418 was sufficient to greatly reduce colony formation by mock-infected HPP-CFC, while this concentration of G418 had little or no effect on CFU-GEMM, BFU-E, or CFU-GM. At 1.5 mg/ml G418, 4.2, 72.0, 82.0, and 97%, respectively, of HPP-CFC, CFU-GEMM, BFU-E, and CFU-GM formed colonies (Table 3 A). 26 of 27 of these G418-colonies were positive by PCR analysis for the TK-neo gene (Table 3 B, Fig. 1). At 12 μg/ml G418, 85% of the HPP-CFC survived to form colonies (Table 3 A) and 11 of 12 of these colonies were positive to PCR analysis for the TK-neo gene (Table 3 B, Fig. 1). Also, as shown in Table 3 B, suspension cultures derived from single progenitors incubated with virus supernatant containing the TK-neo gene and grown in the presence of 1.5 mg/ml G418 were positive in 6 of 6 wells for the TK-neo gene by PCR analysis.

Since we found that it was not possible to wash single cells after sorting the cells into single wells without losing the cells, the single sorted cells were not washed free of the viral supernatant containing the TK-neo gene. Other means were thus used to evaluate whether the virus added to the single cells was transducing the TK-neo gene into the original sorted progenitor cell, or whether the possibility existed that immediate or subsequent daughter cells were being infected after the progenitor or daughter cells had divided. To this end, we first evaluated the transducing stability of the viral supernatant containing the TK-neo gene at 37°C (incubation temperature). Viral supernatant was incubated at 37°C for 6, 24,

| Table 3. G418-Colonies Derived from Single CD34+ Cord Blood Cells Transduced with Neo Gene at the Single Cell Level and Neo Gene Detection by PCR Analysis of Individual Primary G418- Colonies* |
|------------------|------------------|------------------|------------------|------------------|
| A Primary colonies or cells growing with G418 at concentrations of: | Percent G418- colonies |
| 1.5 mg/ml | 58 (85/147) | 4.2 (2/48) | 72 (26/36) | 97 (35/36) | 81 (22/27) |
| 1.2 μg/ml | 80 (117/147) | 85 (41/48) | 69 (25/36) | 86 (31/36) | 74 (20/27) |
| B Cells analyzed from Primary colonies growing with G418 at 1.5 mg/ml | Percent colonies positive for Neo gene by PCR analysis |
| 96 [26/27] | ND | 100 [9/9] | 100 [9/9] | 89 [8/9] |
| Primary colonies growing with G418 at 12 μg/ml | 92 [11/12] | 92 [11/12] | ND | ND | ND |
| Suspension cultures with G418 at 1.5 mg/ml | 100 [6/6] |

* Single CD34+ cells were sorted into single wells in either methylcellulose culture or suspension culture with Epo, SLF, IL-3, and GM-CSF and incubated for 3 or 4 d. Viral supernatant was then added as 20 μl/well with polybrene. G418 was added at either 1.5 mg/ml or 12 μg/ml 24 h after gene transduction. Neo gene was detected by PCR analysis of G418- colonies cells.

1 The numbers in parentheses designate the number of colonies growing in G418 per total number of colonies growing without G418.

2 The numbers in brackets designate the number of colonies positive for the new gene per total number of colonies evaluated.

1 ND, not done.

2092  Gene Transduction into Isolated Stem/Progenitors
Figure 1. Neo gene expression determined by PCR analysis of individual colonies derived from single CD34+ cord blood cells transduced with TK-neo gene directly at the level of 1 cell/well. (A) Cells that grew in suspension culture with G418 at 1.5 mg/ml and primary HPP-CFC colonies growing with G418 at 12 μg/ml; (B) Primary colonies from CFU-GEMM, CFU-GM, and BFU-E derived from CD34+ cells growing in presence of G418 at 1.5 mg/ml. Products of a standard amplification reaction of 30 cycles separated by electrophoresis on a 1% agarose gel, transferred to Gene Screen Plus, and hybridized with 32P-labeled neo fragment formed 1 band of 792bp. (+) Indicates DNA extracted from NIH3T3 cells infected with TK-neo gene as a positive control. (-) Indicates DNA extracted from NIH3T3 cells without TK-neo infection as a negative mock control.

Table 4. Neo Gene Detection by PCR Analysis of Secondary Colonies Deriving from Primary G418R-HPP-CFC and -CFU-GEMM Colonies*

| No. of secondary colonies from: | No. experiments | No. colonies evaluated | Total HPP-CFC | CFU-GM | BFU-E | CFU-GEMM |
|--------------------------------|----------------|-----------------------|---------------|--------|-------|---------|
| HPP-CFC growing with G418 at 12 μg/ml | 1              | 8                     | 8             | 5      | 3     | NA†     | NA      |
| CFU-GEMM growing with G418 at 1.5 mg/ml | 2              | 30                    | 30            | NA     | 13    | 5       | 12      |

* CD34+ cells transduced with the Neo gene were sorted at 1 cell/well in the presence of the above concentrations of G418. G418R-HPP-CFC and -CFU-GEMM colonies were replated into 20 dishes in the absence of G418 and the resultant 20 colonies were analyzed for the Neo gene.
† NA, not applicable because HPP-CFC colonies did not give rise to BFU-E or CFU-GEMM colonies and CFU-GEMM colonies did not give rise to HPP-CFC colonies when replated into 20 dishes.

and 48 h and these treated viral samples were compared to viruses not subjected to 37°C for their capacity to transduce NIH 3T3 cells as assessed by the growth of G418R (1.5 mg/ml)–NIH 3T3 colony forming cells. Viruses incubated for 6, 24, and 48 h at 37°C, respectively, produced 50, 0, and 0 G418R colonies compared with the >150 colonies formed from NIH 3T3 cells incubated with nonheat-treated virus. Thus, the transducing capacity of the virus was completely lost between 6 and 24 h incubation of the virus at 37°C. Examination of CD34+ cells sorted as a single cell/well demonstrated that at a time that was equivalent to 24 h after the addition of virus to the single cells, >97% of the wells still contained only single cells. The remainder of the wells contained doublets. Together, the above information suggests that in >97% of the cases, the TK-neo gene was likely transduced into a single isolated CD34+ progenitor cell.

Stable Gene Transduction into Replatable HPP-CFC and CFU-GEMM. We have previously demonstrated that colonies derived from single isolated CD34+ cord blood HPP-CFC/well have extensive replating capacity (25) and that cord blood...
CFU-GEMM can be replated with high efficiency (30, 31). Single colonies in primary plates derived from single CD34+ HPP-CFC/well and incubated with viral supernatant containing the TK-neo gene and cultured with 12 μg/ml G418, and single colonies from single CD34+ CFU-GEMM/well incubated with viral supernatant containing the TK-neo gene and cultured with 1.5 mg/ml G418 were replated into secondary culture plates. 50 primary HPP-CFC colonies were individually placed into secondary dishes with a replating efficiency of 62%. Secondary plates contained HPP-CFC colonies, which were at least as large as the primary colonies from which they were derived, containing tens of thousands of cells, and also CFU-GM colonies. 98 primary CFU-GEMM colonies were individually placed into secondary dishes with a replating efficiency of 69%. Secondary plates included CFU-GEMM-, BFU-E-, and CFU-GM colonies. Results in Table 4 and Fig. 2 demonstrated that the TK-neo gene was detected in 100% of the secondary colonies demonstrating stable integration into subsets of stem/progenitor cells that have replating capacity.

Discussion

Gene therapy may be an option for the treatment of certain genetic disorders (3, 4) and in this context retroviral containing vectors have been used to transduce genes into hematopoietic stem and progenitor cells (1, 2, 5-20, 37). Cord blood stem/progenitor cells have been used to clinically transplant and correct a number of blood disorders (32-36), and this source of cells may be especially useful for gene therapy in an autologous situation for newborns and young children. The use of cord blood cells for such purposes is highlighted by the enhanced frequency and quality of immature stem/progenitor cells in cord blood compared to adult bone marrow (25-31), and the more efficient transduction of progenitors and long-term culture initiating cells in relatively unseparated cord blood by retroviral-mediated gene transfer (37). It is our feeling that the future of gene therapy in the setting of stem/progenitor cells will not only entail the use of highly enriched fractions of these cells, but also, as technology for characterizing and isolating subsets of these cells based on their self-renewal, proliferative, and lineage differentiation capacities becomes available, it will be these isolated and distinct subsets that will be used as target cells for this purpose. Currently, antigenic profiles available for human stem-progenitor cells only allow for very small degrees of separation of subsets of these cell populations (23, 25).

In the present study, we have not only demonstrated a very high degree of efficiency of stable gene transduction into very highly purified stem/progenitor cells from cord blood, but we have shown this capability at the level of a single isolated CD34+ cell. This opens up the possibility in the future that as different subtypes of stem/progenitors become recognizable antigenically, single such cells can be efficiently transduced with genes. That the genes were put into immature cells is suggested by the fact that the cells containing the genes were stimulated to proliferate by multiple growth factors that are necessary to induce early subsets of cells to grow (25, 39, 42), and by the extensive replating capacity of the transduced HPP-CFC and CFU-GEMM. The high efficiency of gene transduction may relate to the combination of potent growth factors used in the pretreatment phase, and also the use of few cells per volume of vector-containing supernatant. An especially high transduction efficiency was apparent when single CD34+ cells were used. Interestingly, we had to use no G418, or low amounts of G418 to demonstrate the high rate of gene transduction of HPP-CFC, due to the hypersensitivity of HPP-CFC to inhibition by G418. Our studies demonstrate that high efficiency gene transduction is feasible in the absence of vector-producing stromal cells, an extremely important consideration if one wishes to use the transduced cells for transplantation without worry of potential graft vs. host reactions that may occur from infusion into patients of contaminating vector-producing stromal cells. Also, our studies demonstrate high efficiency gene transduction in the complete absence of accessory cells as rigorously determined by the single cell studies.

Engraftment and repopulation of the hematopoietic system appears to require marrow repopulating cells as well as more mature short-term engrafting cells. Unfortunately, there is no assay yet available that definitively characterizes human marrow repopulating cells. Stem as well as progenitor cell populations entail a hierarchy of cells within each category from more immature to more mature. A human cell that has the expected characteristics of early subsets of stem cells has been identified (43) but whether this human cell population contains long-term marrow repopulating cells remains to be determined. The cells assessed in this current report are not considered to be long-term marrow repopulating cells, but HPP-CFC and CFU-GEMM can be considered to be at least subsets of more mature stem cells based on the extensive replating capacity of the primary colonies derived from these cells (25, 30, 31). From bone marrow transplantation studies using CD34+ cells (34) it is likely that our population of sorted CD34+ cells contain long-term marrow engrafting cells. It remains to be determined, as soon as an appropriate assay is available, whether the human marrow repopulating cells are also transducible with genes at the efficiency noted in our study for HPP-CFC, CFU-GEMM, BFU-E, and CFU-GM.
These studies were supported by Public Health Service Grants R37 CA 36464 (National Cancer Institute), R01 HL-46549, and R01 HL-49202 (National Institutes of Health) to H. E. Broxmeyer, and a grant from the Phi Beta Psi Sorority to L. Lu. D. W. Clapp is a recipient of a Clinical Investigator Award of the National Heart, Lung, and Blood Institute, National Institutes of Health, and is a Basil O'Connor Scholar of the March of Dimes.

Address correspondence to Hal E. Broxmeyer, Ph.D. and Li Lu, M.D., Walther Oncology Center, Indiana University School of Medicine, 975 West Walnut Street, IB 501, Indianapolis, IN 46202-5121.

Received for publication 30 July 1993.

References

1. Bernstein, A., S. Berger, D. Hyszr, and J. Dick. 1985. Gene transfer with retrovirus vectors. In Genetic Engineering: Principles and Methods. Vol. 7 J.K. Seton and A. Hollander, editors. Plenum Press, New York. 235 pp.

2. Williams, D.A., and S.H. Orkin. 1986. Somatic gene therapy. Current status and future prospects. J. Clin. Invest. 77:1053.

3. Anderson, W.F. 1992. Human gene therapy. Science (Wash. DC). 256:808.

4. Miller, A.D. 1992. Human gene therapy comes of age. Nature (Lond.). 357:455.

5. Joyner, A., G. Keller, R.A. Phillips, and A. Bernstein. 1983. Retrovirus transfer of a bacterial gene into mouse hematopoietic progenitor cells. Nature (Lond.). 305:556.

6. Miller, A.D., R.J. Eckner, D.J. Jolly, T. Friedman, and I.M. Verma. 1984. Expression of a retrovirus encoding human HPRT in mice. Science (Wash. DC). 225:630.

7. Williams, D.A., I.R. Lemischka, D.G. Nathan, and R.C. Mulligan. 1984. Introduction of new genetic material into pluripotent hematopoietic stem cells of the mouse. Nature (Lond.). 310:476.

8. Eglitis, M.A., P. Kantoff, E. Gilboa, and W.F. Anderson. 1985. Gene expression in mice after high efficiency retroviral-mediated gene transfer. Science (Wash. DC). 230:1395.

9. Keller, G., C. Paige, E. Gilboa, and E.F. Wagner. 1985. Expression of a foreign gene in myeloid and lymphoid cells derived from multipotent hematopoietic precursors. Nature (Lond.). 318:149.

10. Dick, J.E., M.C. Magli, D. Huszar, R.A. Phillips, and A. Bernstein. 1985. Introduction of a selectable gene into primitive stem cells capable of long-term reconstitution of the hematopoietic system of W/W' mice. Cell. 42:71.

11. Williams, D.A., S.H. Orkin, and R.C. Mulligan. 1986. Retrovirus-mediated transfer of human adenosine deaminase gene sequences into cells in culture and into murine hematopoietic cells in vivo. Proc. Natl. Acad. Sci. USA. 83:2566.

12. Williams, D.A., K. Hsieh, A. DeSilva, and R.C. Mulligan. 1987. Protection of bone marrow transplant recipients from lethal doses of methotrexate by the generation of methotrexate-resistant bone marrow. J. Exp. Med. 166:210.

13. Kantoff, P.W., A.P. Gillio, J.R. McLachlin, C. Bordignon, M.A. Eglitis, N.A. Kernan, R.C. Moen, D.B. Kohn, S-F. Yu, E. Karson, et al. 1987. Expression of human adenosine deaminase in nonhuman primates after retrovirus-mediated gene transfer. J. Exp. Med. 166:219.

14. Lim, B., D.A. Williams, and S.H. Orkin. 1987. Retrovirus-mediated gene transfer of human adenosine deaminase: expression of functional enzyme in murine hematopoietic stem cells in vivo. Mol. Cell. Biol. 7:3459.

15. Lim, B., J.F. Apperley, S.H. Orkin, and D.A. Williams. 1989. Long-term expression of human adenosine deaminase in mice transplanted with retrovirus-infected hematopoietic stem cells. Proc. Natl. Acad. Sci. USA. 86:8892.

16. Bodine, D.M., K.T. McDonagh, S.J. Brandt, P.A. Noy, B. Agnelli, E. Byrne, and A.W. Nienhuis. 1990. Development of a high-titer retrovirus producer cell line capable of gene transfer into rhesus monkey hematopoietic stem cells. Proc. Natl. Acad. Sci. USA. 87:3738.

17. Clapp, D.W., L.L. Dumenico, M. Hatzoglou, and S.L. Gerson. 1991. Fetal liver hematopoietic stem cells as a target for in utero retroviral gene transfer. Blood. 78:1132.

18. Nolta, J.A., G.M. Crooks, R.W. Overell, D.E. Williams, and D.B. Kohn. 1992. Retroviral vector-mediated gene transfer into primitive human hematopoietic progenitor cells: effects of mast cell growth factor (MGF) combined with other cytokines. Exp. Hematol. (NY). 20:1065.

19. Pharr, P.N., D. Hanks, A. Hofbauer, H.F. Lodish, and G.D. Longmore. 1993. Expression of a constitutively active erythropoietin receptor in primary hematopoietic progenitors abrogates erythropoietindependence and enhances erythroid colony-forming unit, erythroid burst-forming unit, and granulocyte/macrophage progenitor growth. Proc. Natl. Acad. Sci. USA. 90:938.

20. Cassel, A., M. Cottler-Fox, S. Doren, and C.E. Dunbar. 1993. Retroviral-mediated gene transfer into CD34-enriched human peripheral blood stem cells. Exp. Hematol. (NY). 21:585.

21. Ferrari, G., S. Rossini, N. Nobili, D. Maggioni, A. Garofalo, R. Giavazzi, F. Pavillo, and C. Bordignon. 1992. Transfer of the ADA gene into human ADA-deficient T lymphocytes reconstitutes specific immune functions. Blood. 80:1120.

22. Gansbacher, B., K. Zier, K. Cronin, P.A. Hatzopoulos, B. Bouchard, A. Houghton, E. Gilboa, and D. Golde. 1992. Retroviral gene transfer induced constitutive expression of interleukin-2 or interferon-gamma in irradiated human melanoma cells. Blood. 80:2817.

23. Lu L., D. Walker, H.E. Broxmeyer, R. Hoffman, W. Hu, and E. Walker. 1987. Characterization of adult human marrow hematopoietic progenitors highly enriched by two-color sorting with My-10 and major histocompatibility (MHC) class II monoclonal antibodies. J. Immunol. 139:1823.

24. Berenson, R.J., W.L. Bensigner, R.S. Hill, R.G. Andrews, J. Garcia-Lopez, D.F. Kalomasz, B.J. Still, G. Spitzer, C.D. Buckner, I.D. Bernstein, and E.D. Thomas. 1991. Engraftment after infusion of CD34+ marrow cells in patients with breast cancer or neuroblastoma. Blood. 77:1717.

25. Lu L., M. Xiao, R-N. Shen, S. Grisby, and H.E. Broxmeyer. 1993. Enrichment, characterization and responsiveness of single
primitive CD34+ human umbilical cord blood hematopoietic progenitors with high proliferative and replating potential. Blood. 81:41.

26. Broxmeyer, H.E., G.W. Douglas, G. Hangoc, S. Cooper, J. Bard, D. English, M. Arny, L. Thomas, and E.A. Boyse. 1989. Human umbilical cord blood as a potential source of transplantable hematopoietic stem/progenitor cells. Proc. Natl. Acad. Sci. USA. 86:3828.

27. Broxmeyer, H.E., G. Hangoc, S. Cooper, R. Ribeiro, V. Graves, M. Yoder, J. Wagner, S. Vadhan-Raj, L. Benninger, P. Rubinstein, and E.R. Broun. 1992. Growth characteristics and expansion of human umbilical cord blood and estimation of its potential for transplantation in adults. Proc. Natl. Acad. Sci. USA. 89:4109.

28. Hows, J.M., B.A. Bradley, J.C. Marsh, T. Luft, L. Coutinho, N.G. Testa, and T.M. Dexter. 1992. Growth of human umbilical cord blood in long term haematopoietic cultures. Lancet. 340:73.

29. Cardoso, A.A., M.L. Li, A. Hatzfeld, E.L. Brown, J.P. Levesque, H. Soookdeo, P. Batard, S.C. Clark, and J. Hatzfeld. 1993. Release from quiescence of CD34+ CD38− human umbilical cord blood cells reveals their potentiality to engraft adults. Proc. Natl. Acad. Sci. USA. 90:8707.

30. Carow, C.E., G. Hangoc, S. Cooper, D.E. Williams, and H.E. Broxmeyer. 1991. Mast cell growth factor (c-kit ligand) supports the growth of human multipotential (CFU-GEMM) progenitor cells with a high replating potential. Blood. 78:2216.

31. Carow, C.E., G. Hangoc, and H.E. Broxmeyer. 1993. Human multipotential progenitor cells (CFU-GEMM) have extensive replating capacity for secondary CFU-GEMM; an effect enhanced by cord blood plasma. Blood. 81:942.

32. Gluckman, E., H.E. Broxmeyer, A.D. Auerbach, H. Friedman, G.W. Douglas, A. Devergie, H. Esperou, D. Thierry, G. Socie, P. Lehn, et al. 1989. Hematopoietic reconstitution in a patient with Fanconi's anemia by means of umbilical cord blood from an HLA-identical sibling. N. Engl. J. Med. 321:1174.

33. Wagner, J.E., H.E. Broxmeyer, R.L. Byrd, B. Zehnbauer, B. Schmeckpeper, N. Shah, C. Griffin, P.D. Emanuel, K.S. Zuckerman, S. Cooper, et al. 1992. Transplantation of umbilical cord blood after myeloblastic therapy: analysis of engraftment. Blood. 79:1874.

34. Vilmer, E., G. Sterkers, C. Rahimy, E. Denamar, J. Elion, A. Broyart, B. Lescoeurt, J.M. Tiercy, J. Gerota, and P. Blot. 1992. HLA-mismatched cord blood transplantation in a patient with advanced leukemia. Transplantation (Baltimore). 53:1155.

35. Kohli-Kumar, M., N.T. Shahidi, H.E. Broxmeyer, M. Masterson, C. Dlaat, J. Sambrano, C. Morris, A.D. Auerbach, and R.E. Harris. 1993. Haematopoietic stem/progenitor cell transplant in Fanconi anemia using HLA-matched sibling umbilical cord blood cells. Br. J. Haematol. In press.

36. Vowels, M.R., R.L.P. Tang, V. Bendoukas, D. Ford, D. Thierry, D. Purtill, and E. Gluckman. 1993. Correction of x-linked lymphoproliferative disease by cord blood transplantation. N. Engl. J. Med. In press.

37. Moritz, T., D.C. Keller, and D.A. Williams. 1993. Human cord blood cells as targets for gene transfer. Potential use in genetic therapies of severe combined immunodeficiency disease. J. Exp. Med. 178:529.

38. Bernstein, I.D., R.G. Andrews, and K.M. Zsebo. 1991. Recombinant human stem cell factor enhances the formation of colonies by CD34+ and CD34−lin− cells, and the generation of colony-forming cell progeny from CD34+lin− cells cultured with interleukin-3, granulocyte colony-stimulating factor, or granulocyte-macrophage colony-stimulating factor. Blood. 77:2316.

39. Xiao, M., T. Leemhuis, H.E. Broxmeyer, and L. Lu. 1992. Influence of combinations of cytokines on proliferation of isolated single cell-sorted human bone marrow hematopoietic progenitor cells in the absence and presence of serum. Exp. Hematol. (NY). 20:276.

40. Higuchi R. 1989. Rapid efficient DNA extraction for PCR from cells or blood. In Amplifications, A Forum for PCR Users. Perkin-Elmer Cetus, Norwalk, CT: 2.1.

41. Winberg, G. 1991. A rapid method for preparing DNA from blood, suited for PCR screening of transgenes in mice. PCR Methods and Applications. 1:72.

42. Broxmeyer, H.E., B. Sherry, L. Lu, S. Cooper, K.O. Oh, P. Tekamp-olson, B.S. Kwon, and A. Cerami. 1990. Enhancing and suppressing effects of recombinant murine macrophage inflammatory proteins on colony formation in vitro by bone marrow myeloid progenitor cells. Blood. 76:1110.

43. Baum, C.M., I.L. Weissman, A.S. Tsukamoto, A.-M. Buckle, and B. Peault. 1992. Isolation of a candidate human hematopoietic stem-cell population. Proc. Natl. Acad. Sci. USA. 89:2804.